FLGT News and Press, Fulgent Genetics Inc. From 04/18/19

TEMPLE CITY, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its first quarter 2019 financial results after the market closes on Tuesday May 7, 2019. The c...

Fulgent Genetics ( FLGT ) is a genetic testing contractor with proprietary technology enabling a host of different genetic tests. The share price has been on a roll lately, but we think after some consolidation, this could resume as the shares still aren't all that expensive. The evolution h...

Fulgent Genetics, Inc. (FLGT) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Nicole Borsje – Head of Investor Relations Ming Hsieh – Chief Executive Officer Paul Kim – Chief Financial Officer Conference Call Participants...

Fulgent Genetics (NASDAQ: FLGT ): Q4 Non-GAAP EPS of $0.01 beats by $0.02 ; GAAP EPS of -$0.05 misses by $0.02 . More news on: Fulgent Genetics, Earnings news and commentary, Healthcare stocks news, , Read more ...

Fourth Quarter 2018 Results : Revenue totals $5.7 million, growing 33% year over year Billable tests delivered total 6,408, growing 52% year over year GAAP loss of $935,000, or $0.05 per share Non-GAAP loss of $193,000, or $0.01 per share Adjusted EBITDA of $50,000 Full Year 20...

TEMPLE CITY, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its fourth quarter and full year 2018 financial results after the market closes on Thursday Feb...

Fulgent Genetics (NASDAQ: FLGT ): Q3 Non-GAAP EPS of $0.00 beats by $0.04 ; GAAP EPS of -$0.03 beats by $0.01 . More news on: Fulgent Genetics, Earnings news and commentary, Healthcare stocks news, , Read more ...

Third Quarter 2018 Results : Revenue totals $5.6 million, growing 25% year over year and 4% sequentially Billable tests delivered total 5,569, growing 37% year over year GAAP gross margin improves 70 basis points sequentially Non-GAAP gross margin remains flat sequentially GAAP los...

TEMPLE CITY, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its third quarter 2018 financial results after the market closes on Tuesday November 6, 2018. T...

BALDWIN PARK, Calif. , Oct. 9, 2018 /PRNewswire/ -- StemCyte, a global regenerative therapeutics company, and Fulgent Genetics (NASDAQ:FLGT), a leading genetic testing company, are proud to announce a new partnership to offer comprehensive genetic testing to support the health of growing ...